Abstract
Astellas Pharma aims to secure a top share in the Japanese pharmaceutical
market. This report provides a full review of the company's activities
together with sales forecasts for key products to 2010.
Astellas Pharma (Fujisawa and Yamanouchi) recorded consolidated net sales for
the first nine months of fiscal 2005/6 of ¥678,848 million, a 2% increase over
the same period in 2004/5. This result was negatively impacted by various
factors related to the merger, including product transfers and divestiture of
non-ethical pharmaceutical businesses, which combined to reduce consolidated
net sales by approximately ¥29.2 billion. Sales of ethical pharmaceuticals
rose by 2% to ¥653.2 billion and R&D expenditure amounted to ¥92,590 million,
an increase of 3%.
R&D Pipeline Overview
- FK506 is an asthma treatment in Phase II in the US and Europe.
- YM060, an oral agent to treat diarrhoea-predominant irritable bowel
syndrome (IBS), is currently in Phase II in Europe and Phase III in Japan with
launch expected in 2006.
- YM150 is an oral antithrombotic agent for the treatment of venous
thromboembolism.
- RSD1235 is an anti-arrhythmic agent and is being co-developed with
Cardiome in Canada, US and Mexico, as an iv formulation for the treatment of
atrial fibrillation and atrial flutter.
- CVT-3146: Astellas is co-developing regadenoson (CVT-3146), a
short-acting, selective A2A adenosine-receptor agonist, with CV Therapeutics.
CV Therapeutics advanced CVT-3146 into a Phase III trial in 2003.
In all, Astellas Pharma has 15 late stage compounds expected to enter the
market over the next 5 years.
Major Products Forecast to 2010
- Gaster/Pepcid (Gastrointestinal)
- Nasea (Anti-emetic)
- Ketek (Antibiotic)
- Cefzon (Antibiotic)
- Lipitor (Cardiovascular)
- Perdipine (Cardiovascular)
- Hypoca/Cyress (Cardiovascular)
- Micardis (Cardiovascular)
- Protopic (Transplantation/Arthritis)
- Starsis (Diabetes)
View Cart
